Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
2008
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Targeted therapies for breast cancer
2011
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
2010
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
2008
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
2010
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
2011
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
2008
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
2009
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
2009
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
2012
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
2012
Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation
2011
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
2013
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
2012
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
2011
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
2011
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
2011
Estrogen receptors and human disease
2006 Standout
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Role of estrogens in development of prostate cancer
2004
Targeted Therapy for Breast Cancer
2013
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy
2015
Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes
2014 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Trastuzumab: triumphs and tribulations
2007
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
2015
Evaluation of automated silver‐enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens
2009
Breast cancer genomes — form and function
2010
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Cancer immunotherapy comes of age
2011 StandoutNature
Biomarkers of response and resistance to antiangiogenic therapy
2009
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
2014
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Progression of Renal Disease and Renal Hypertrophy
1995
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
2010
Cervical cancer
2019 Standout
HeterogeneousHER2Gene Amplification
2011
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Deconstructing the molecular portraits of breast cancer
2010
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
2008
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Breast Cancer Treatment
2019 Standout
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
2015
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
2010
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
2015
Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results
2009
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of Steven Stein being referenced
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
2008
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
2009
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment
2009
Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
2008
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Phase II Trial of Toremifene in Androgen-Independent Prostate Cancer
2001
Compensatory Renal Hypertrophy: The Role of Immediate Vascular Changes in its Production
1970